Clinical trial Recruiting at 4 sites Interventional Ages 18 and up

Preventing infections in hemodialysis patients with antibiotics

Official title: Prophylactic Antibiotic Treatment in End Stage Kidney Disease and Central Venous Catheter as Hemodialysis Vascular Access

Run by Zealand University Hospital · NCT05248620 · Data updated 2026-11-12

This study is testing if giving antibiotics to people starting hemodialysis can help prevent serious infections during their treatment.

More Hemodialysis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment800 (estimated)
SponsorZealand University Hospital
Academic / other
Locations7 sites (Copenhagen, Capital Region and 6 other locations)
StatusRecruiting
StartedFebruary 14, 2022
Main results expectedOctober 2028
Study endsMay 2029
Registry record updatedSeptember 10, 2026
Trial IDNCT05248620 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with end-stage kidney disease requiring hemodialysis via a central venous catheter.

Probably not a fit

Patients who are intolerant to beta-lactam antibiotics or clindamycin, or those with active infections being treated with antibiotics will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of prophylactic antibiotic treatment in preventing blood stream infections and severe culture negative infections in patients starting hemodialysis with a central venous catheter. Eligible participants will be randomly assigned to receive either amoxicillin/clavulanic acid or a placebo before each hemodialysis session for a duration of six months. The study aims to establish a sufficient concentration of antibiotics during dialysis sessions to reduce infection rates. Participants will be monitored for side effects and followed up for one year after treatment.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the incidence of infections in hemodialysis patients, improving their overall health outcomes.

How similar studies have gone: Previous studies have shown promising results with prophylactic antibiotics in similar patient populations, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft))
* ≥18 years
* Ability to understand the study background, risk and benefit of treatment and to give written informed consent

Exclusion Criteria:

* Unable to give informed consent
* Known intolerance to beta-lactam antibiotics and clindamycin
* Active infection treated with antibiotics
* Breastfeeding
* Pregnancy. In women of childbearing age, an approved birth control must be ensured at least 1 month before and during all the 6 months of antibiotic/placebo treatment.

Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible.

Where it's running

  • Herlev-Gentofte Hospital
    Copenhagen, Capital Region, Denmark
    Recruiting
  • Aalborg University Hospital
    Aalborg, North Region, Denmark
    Recruiting
  • ZUH Roskilde
    Roskilde, Region Sjælland, Denmark
    Recruiting
  • Odense University Hospital
    Odense, Region South, Denmark
    Recruiting
  • Rigshospitalet
    Copenhagen, Capital Region, Denmark
    Not yet recruiting
  • North Zealand Hospital Hillerød
    Hillerød, Capital Region, Denmark
    Not yet recruiting
Show 1 more location
  • Aarhus University Hospital
    Aarhus, Middle Region, Denmark
    Not yet recruiting

Study contacts

  • Principal investigator: Niels E Bruun, Professor — Dept. cardiology, Zealand University Hospital, Roskilde, Denmark
  • Study coordinator: Niels E Bruun, Professor
  • Email: nbru@regionsjaelland.dk
  • Phone: +4525159309

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.